To appraise the clinical and cost-effectiveness of atezolizumab in combination with gemcitabine and carboplatin within its marketing authorisation for urothelial carcinoma
Following on from information provided to NICE by the company in March 2021, the appraisal of Atezolizumab in combination with platinum-based chemotherapy for untreated locally advanced or metastatic urothelial cancer [ID1206] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
 
Status Discontinued
Technology type Medicine
Decision Selected
Process TA
ID number 1206

Email enquiries

External Assessment Group Southampton Health Technology Assessment Centre (SHTAC), University of Southampton

Stakeholders

Companies sponsors Roche (Atezolizumab with gemcitabine and carboplatin)
Others Department of Health and Social Care
  NHS England
  NHS Greater Preston CCG
  NHS Hartlepool and Stockton-on-Tees CCG
  Welsh Government
Patient carer groups Action Bladder Cancer UK
  Black Health Agency for Equality
  Bladder and Bowel Community
  Bladder and Bowel UK
  Cancer 52
  Cancer Black Care
  Cancer Equality
  Fight Bladder Cancer
  Helen Rollason Cancer Charity
  Independent Cancer Patients Voice
  Macmillan Cancer Support
  Maggie’s Centres
  Marie Curie
  Pelican Cancer Foundation
  South Asian Health Foundation
  Specialised Healthcare Alliance
  Tenovus Cancer Care
Professional groups Association of Cancer Physicians
  British Association of Urological Nurses
  British Association of Urological Surgeons
  British Geriatrics Society
  British Gynaecological Cancer Society
  British Institute of Radiology
  British Psychosocial Oncology Society
  British Society of Urogenital Radiology
  British Society of Urogynaecology
  British Uro-Oncology Group
  Cancer Research UK
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Pathologists
  Royal College of Physicians
  Royal College of Radiologists
  Royal Pharmaceutical Society
  Royal Society of Medicine
  Society and College of Radiographers
  UK Clinical Pharmacy Association
  UK Oncology Nursing Society
  Urology Foundation
Associated guideline groups National Guideline Centre
Associated public health groups Public Health England
  Public Health Wales
Comparator companies Accord Healthcare (carboplatin, cisplatin, doxorubicin, gemcitabine, methotrexate)
  Allergan (gemcitabine)
  Amgen (pegfilgrastim)
  Chugai Pharma (lenograstim)
  Concordia International (methotrexate)
  Hospira UK (carboplatin, cisplatin, gemcitabine, methotrexate, vinblastine)
  Janssen-Cilag (doxorubicin)
  Lilly UK (gemcitabine)
  Medac GmbH (doxorubicin, gemcitabine)
  Merck Sharp & Dohme (pembrolizumab)
  Nordic Pharma (methotrexate)
  Orion Pharma (methotrexate)
  Pfizer (doxorubicin, methotrexate, vinblastine)
  Rosemont Pharmaceuticals (methotrexate)
  Sandoz (cisplatin, methotrexate)
  Seacross Pharmaceuticals (doxorubicin)
  Sun Pharma (carboplatin, gemcitabine)
  Teva UK (doxorubicin, lipegfilgrastim, methotrexate)
  Therakind (methotrexate)
General commentators All Wales Therapeutics and Toxicology Centre
  Allied Health Professionals Federation
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  National Association of Primary Care
  National Pharmacy Association
  NHS Alliance
  NHS Confederation
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups Cochrane Urology
  Genomics England
  Institute of Cancer Research
  MRC Clinical Trials Unit
  National Cancer Research Institute
  National Cancer Research Network
  National Institute for Health Research
  Leeds Institute of Cancer & Pathology

Timeline

Key events during the development of the guidance:

Date Update
21 November 2022 Following on from information provided to NICE by the company in March 2021, the appraisal of Atezolizumab in combination with platinum-based chemotherapy for untreated locally advanced or metastatic urothelial cancer [ID1206] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
21 November 2022 Discontinued. Following on from information provided to NICE by the company in March 2021, the appraisal of Atezolizumab in combination with platinum-based chemotherapy for untreated locally advanced or metastatic urothelial cancer [ID1206] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
16 November 2020 Suspended. The company has informed NICE that it will not provide an evidence submission for this appraisal. Therefore, we are suspending the appraisal while we consider the next steps.
28 August 2020 Invitation to participate
18 May 2020 The Department for Health and Social Care has asked NICE to conduct an appraisal of atezolizumab in combination with platinum-based chemotherapy for the first-line treatment of adult patients with locally advanced or metastatic urothelial bladder cancer. Please note that following on from advice received from the company the timelines for this appraisal have been revised and we now anticipate that the appraisal will begin during late August 2020 when we will write to you about how you can get involved.
21 November 2019 - 28 November 2019 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
09 February 2018 In progress. Topic referred 21 April 2017

For further information on our processes and methods, please see our CHTE processes and methods manual